Protocol Ledger

NCT05461794 · Phase II · TERMINATED

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Interventional Phase II clinical trial protocol NCT05461794 sponsored by BeiGene in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-10-03 Enrollment: 96 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05461794
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)96 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05461794
Protocol FieldVerified Registry Value
NCT IdentifierNCT05461794
Consolidated Lead SponsorBeiGene
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment96 participants (ACTUAL)
Registered Start Date2022-10-03
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI